# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- Reuters
"We are very pleased that mRNA-1283 has now met its primary vaccine efficacy endpoint in Phase 3, and showed higher efficac...
Oppenheimer analyst Hartaj Singh maintains Moderna (NASDAQ:MRNA) with a Outperform and raises the price target from $163 to ...
- Reuters Citing Goldman Sachs Conference
Moderna said its Phase 3 trial of mRNA-1083, an investigational combination vaccine against influenza and COVID-19, met its pri...
Liz Young of SoFi recommends Energy Select Sector SPDR Fund as her final trade on CNBC's Halftime Report. Jim Lebenthal of ...